From Wikipedia, the free encyclopedia
Chemical compound
18-Methoxycoronaridine
Other names (−)-18-methoxycoronaridine Zolunicant
Routes of administration
Oral
Legal status
methyl (1S,15R,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
CAS Number
PubChem
CID
ChemSpider
UNII
CompTox Dashboard (
EPA )
Formula C 22 H 28 N 2 O 3
Molar mass 368.477 g·mol−1 3D model (
JSmol )
COCC[C@H]1C[C@@H]2C[C@@]3([C@H]1N(C2)CCc4c3[nH]c5c4cccc5)C(=O)OC
InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1
N Key:DTJQBBHYRQYDEG-SVBQBFEESA-N
N
N Y
(what is this?)
(verify)
18-Methoxycoronaridine (18-MC, or MM-110 ), also known as zolunicant , is a derivative of
ibogaine invented in 1996 by the research team around the pharmacologist
Stanley D. Glick from the
Albany Medical College and the chemists
Upul K. Bandarage and
Martin E. Kuehne from the
University of Vermont . In animal studies it has proved to be effective at reducing self-administration of
morphine ,
cocaine ,
methamphetamine ,
nicotine and
sucrose .
[1]
[2] It has also been shown to produce
anorectic effects in obese rats, most likely due to the same actions on the reward system which underlie its anti-addictive effects against drug addiction.
[3]
18-MC was in the early stages of human testing by the California-based drug development company Savant HWP before being acquired by MindMed, a Canadian pharmaceutical company newly listed on the NASDAQ in April 2021.
[4]
[5] In 2002 the research team began raising funds for human trials, but were unable to secure the estimated $5 million needed.
[6] In 2010, Obiter Research, a chemical manufacturer in
Champaign, Illinois , signed a patent license with
Albany Medical College and the
University of Vermont , allowing them the right to synthesize and market 18-MC and other
congeners . In 2012 the
National Institute on Drug Abuse gave a $6.5 million grant to Savant HWP for human trials.
[5] In 2017 it went into Phase-II trials in Brazil for treatment of
Leishmaniasis at the
Evandro Chagas Institute ,
[7] but not for approval for use as a treatment for drug addiction. A phase 2a study of MM-110 treatment in patients experiencing
opioid withdrawal is set to commence in Q2 2022.
[8]
Pharmacology
18-MC is a
α3 β4
nicotinic antagonist and, in contrast to ibogaine, has no affinity at the
α4 β2 subtype nor at
NMDA-channels nor at the
serotonin transporter ,
[9] and has significantly reduced affinity for
sodium channels and for the
σ receptor , but retains modest affinity for
μ-opioid receptors where it acts as an agonist,
[10] and
κ-opioid receptors .
[11] The sites of action in the brain include the
medial habenula ,
interpeduncular nucleus ,
[12]
[13]
[14] dorsolateral
tegmentum and
basolateral amygdala .
[15] (±)-18-MC competitively inhibits α9α10
nAChRs with potencies higher than that at α3β4 and α4β2 nAChRs and directly blocks
CaV 2.2 .
[16]
Chemistry
Derivatives
A number of derivatives of 18-MC have been developed, with several of them being superior to 18-MC itself, the methoxyethyl congener
ME-18-MC being more potent than 18-MC with similar efficacy, and the methylamino analogue
18-MAC being more effective than 18-MC with around the same potency. These compounds were also found to act as selective
α3 β4 nicotinic acetylcholine antagonists , with little or no effect on NMDA receptors.
[17]
[18]
See also
References
^ Glick SD, Kuehne ME, Maisonneuve IM, Bandarage UK, Molinari HH (May 1996). "18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats". Brain Research . 719 (1–2): 29–35.
doi :
10.1016/0006-8993(96)00056-X .
PMID
8782860 .
S2CID
6178161 .
^ Glick SD, Sell EM, Maisonneuve IM (December 2008).
"Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration" . European Journal of Pharmacology . 599 (1–3): 91–5.
doi :
10.1016/j.ejphar.2008.09.038 .
PMC
2600595 .
PMID
18930043 .
^ Taraschenko OD, Rubbinaccio HY, Maisonneuve IM, Glick SD (December 2008).
"18-methoxycoronaridine: a potential new treatment for obesity in rats?" . Psychopharmacology . 201 (3): 339–50.
doi :
10.1007/s00213-008-1290-9 .
PMC
3787601 .
PMID
18751969 .
^
Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine newswire.ca September 16, 2019.
^
a
b
Albany Med scientist closer to addiction drug success timesunion.com June 27, 2014.
^ Addiction Treatment Strives for Legitimacy. Journal of the American Medical Association . 2002; 288: 3096-3101.
^
"Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients" . ClinicalTrials.gov . Retrieved 19 February 2020 .
^
"Opioid Use Disorder: Zolunicant's Potential for Unmet Treatment Needs" . MindMed.co. 20 May 2022. Retrieved 23 May 2022 .
^ Maisonneuve IM, Glick SD (June 2003). "Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment". Pharmacology, Biochemistry, and Behavior . 75 (3): 607–18.
doi :
10.1016/S0091-3057(03)00119-9 .
PMID
12895678 .
S2CID
26758480 .
^ Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, et al. (2013).
"Effect of Iboga alkaloids on μ-opioid receptor-coupled G protein activation" . PLOS ONE . 8 (10): e77262.
Bibcode :
2013PLoSO...877262A .
doi :
10.1371/journal.pone.0077262 .
PMC
3818563 .
PMID
24204784 .
^ Glick SD, Maisonneuve IM, Hough LB, Kuehne ME, Bandarage UK. (±)-18-Methoxycoronaridine: A Novel Iboga Alkaloid Congener Having Potential Anti-Addictive Efficacy. CNS Drug Reviews 1999;5(1):27-42.
^ Glick SD, Ramirez RL, Livi JM, Maisonneuve IM (May 2006). "18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats". European Journal of Pharmacology . 537 (1–3): 94–8.
doi :
10.1016/j.ejphar.2006.03.045 .
PMID
16626688 .
^ Taraschenko OD, Shulan JM, Maisonneuve IM, Glick SD (July 2007). "18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens". Synapse . 61 (7): 547–60.
doi :
10.1002/syn.20396 .
PMID
17447255 .
S2CID
2252348 .
^ Taraschenko OD, Rubbinaccio HY, Shulan JM, Glick SD, Maisonneuve IM (July 2007).
"Morphine-induced changes in acetylcholine release in the interpeduncular nucleus and relationship to changes in motor behavior in rats" . Neuropharmacology . 53 (1): 18–26.
doi :
10.1016/j.neuropharm.2007.04.010 .
PMC
2025684 .
PMID
17544456 .
^ Glick SD, Sell EM, Maisonneuve IM (December 2008).
"Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration" . European Journal of Pharmacology . 599 (1–3): 91–5.
doi :
10.1016/j.ejphar.2008.09.038 .
PMC
2600595 .
PMID
18930043 .
^ Arias HR, Tae HS, Micheli L, Yousuf A, Ghelardini C, Adams DJ, Di Cesare Mannelli L (September 2020).
"Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and CaV2.2 channels" .
Neuropharmacology . 175 : 108194.
doi :
10.1016/j.neuropharm.2020.108194 .
hdl :
2158/1213504 .
PMID
32540451 .
S2CID
219705597 .
^ Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, et al. (June 2003). "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medicinal Chemistry . 46 (13): 2716–30.
doi :
10.1021/jm020562o .
PMID
12801235 .
^ Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology . 492 (2–3): 159–67.
doi :
10.1016/j.ejphar.2004.03.062 .
PMID
15178360 .
AMPAR Tooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
KAR Tooltip Kainate receptor
NMDAR Tooltip N-Methyl-D-aspartate receptor
nAChRs Tooltip Nicotinic acetylcholine receptors
Agonists (and
PAMs Tooltip positive allosteric modulators )
5-HIAA
6-Chloronicotine
A-84,543
A-366,833
A-582,941
A-867,744
ABT-202
ABT-418
ABT-560
ABT-894
Acetylcholine
Altinicline
Anabasine
Anatabine
Anatoxin-a
AR-R17779
Bephenium hydroxynaphthoate
Butinoline
Butyrylcholine
Carbachol
Choline
Cotinine
Cytisine
Decamethonium
Desformylflustrabromine
Dianicline
Dimethylphenylpiperazinium
Epibatidine
Epiboxidine
Ethanol (alcohol)
Ethoxysebacylcholine
EVP-4473
EVP-6124
Galantamine
GTS-21
Ispronicline
Ivermectin
JNJ-39393406
Levamisole
Lobeline
MEM-63,908 (RG-3487)
Morantel
Nicotine (
tobacco )
NS-1738
PHA-543,613
PHA-709,829
PNU-120,596
PNU-282,987
Pozanicline
Pyrantel
Rivanicline
RJR-2429
Sazetidine A
SB-206553
Sebacylcholine
SIB-1508Y
SIB-1553A
SSR-180,711
Suberyldicholine
Suxamethonium (succinylcholine)
Suxethonium (succinyldicholine)
TC-1698
TC-1734
TC-1827
TC-2216
TC-5214
TC-5619
TC-6683
Tebanicline
Tribendimidine
Tropisetron
UB-165
Varenicline
WAY-317,538
XY-4083
Antagonists (and
NAMs Tooltip negative allosteric modulators )
Precursors (and
prodrugs )